.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EH01_Lapatinib.Lapatinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EH01_Lapatinib.Lapatinib| name: | Lapatinib |
| ATC code: | L01EH01 | route: | oral |
| n-compartments | 2 |
Lapatinib is an oral tyrosine kinase inhibitor targeting both epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). It is primarily used in the treatment of HER2-positive breast cancer, especially in combination with other chemotherapeutics. Lapatinib is approved for use in several countries, including the United States and the EU.
Pharmacokinetic parameters reported in adult female patients with advanced or metastatic HER2-positive breast cancer, following repeated oral administration.
Pai, SM, et al., & Berg, JK (2019). Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis. Journal of clinical pharmacology 59(10) 1379–1383. DOI:10.1002/jcph.1430 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31074516
Nakagawa, K, et al., & Fukuoka, M (2009). Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors. Japanese journal of clinical oncology 39(2) 116–123. DOI:10.1093/jjco/hyn135 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19052038
Guerin, M, et al., & Gonçalves, A (2017). PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. European journal of cancer (Oxford, England : 1990) 86 28–36. DOI:10.1016/j.ejca.2017.08.025 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28950146